Abstract
In advanced non-small cell lung cancer (NSCLC), an objective response to chemotherapy is of limited value and the impact of chemotherapy on survival is modest. Therefore, endpoints evaluating the patients’ subjective benefit such as symptom control (SC), quality of life (QOL) or clinical benefit (CB) have recently been implemented into clinical trials, mostly as secondary endpoints.
Chemotherapy offers SC, not only in patients with an objective response, but also in a proportion of patients with disease stabilization. For this purpose, three to four cycles of platinum-based chemotherapy are recommended.
Interpretation of QOL objectives is limited by several methodologic problems. Studies comparing best supportive care alone with either older platinum-based combinations or single-agent chemotherapy with a new cytotoxic drug usually indicate improved survival and improvement of some component(s) of QOL in the active treatment arm. However, results from studies comparing different chemotherapies are less definitive. Trials comparing single-agent therapy with a new drug with new combinations mostly report no difference in QOL. In addition, most trials comparing new platinum-based combinations with older ones, and trials comparing new platinum-based regimens fail to show any differences in QOL. As a whole, it is far from clear whether combination therapy is superior to modern single-agent therapy, when the patient’s benefit is the primary endpoint. Non-platinum-based doublets, compared with platinum-based doublets, may lead to slightly inferior survival, are not always less toxic, and have not been proven to provide better QOL outcomes.
The CB response, originally reported in pancreatic cancer, measures more than SC, but not full QOL. Encouraging experience with this tool was reported in advanced NSCLC.
Randomized studies designed to look at some form of patient benefit as a primary endpoint should be a priority in advanced NSCLC.
Similar content being viewed by others
References
Souquet P, Chauvin F, Boissel S, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909
Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866–72
Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771–5
Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999; 7: 140–8
Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71: 366–70
Cullen MH, Joshi R, Chetiyawardana AD, et al. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988; 58: 359–61
Osoba D, Rusthoven JJ, Turnbull KA, et al. Combination chemotherapy with bleomycin, etoposide, and cispiatin in metastatic non-small cell lung cancer. J Clin Oncol 1985; 3: 1478–85
Tummarello D, Graziano F, Isidori P, et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cispiatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995; 35: 249–53
Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28: 29–33
Hardy J, Noble T, Smith I. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cispiatin) in advanced non-small cell lung cancer. Cancer 1989; 60: 764–6
Thatcher N, Jayson G, Bradley B, et al. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin Oncol 1997; 24: 6S–12S
Jassem J, Krzakowski M, Roszkowski K, et al. A phase II study of gemcitabine plus cispiatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer 2002; 35: 73–9
Lippe P, Silva RR, Giuliodori L, et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Res 2002; 22: 1053–9
Gridelli C, Perrone F, Palmeri S, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cispiatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial. Ann Oncol 1996; 7: 821–6
Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: analysis of a randomised study. Lung Cancer 2003; 40: 191–9
Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336–43
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199–220
Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993; 29A: S51–8
Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472–83
Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34: 585–97
De Haes JC, Van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034–8
Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998; 16: 3662–73
Kuttner L, LePage T. Face scales for the assessment of pediatric pain: a critical review. Can J Behav Sci 2003; 21: 198–209
Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996; 23: 31S–40S
Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy — general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 1999; 17: 2932–40
Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multi-centre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998; 34: 1036–44
Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17–24
Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1995; 91: 66–72
Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000; 83: 447–53
Cullen MH, Billingham LJ, Woodraffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–94
Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 2001; 12: 1671–5
Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 1074–80
Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145–57
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103
Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–94
Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522–30
Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025–34
Paccagnella A, Favaretto A, Oniga F, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial. Lung Cancer 2004; 43: 83–91
Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122–30
Gatzemeier U, Von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 3390–9
Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 2529–36
Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362–72
Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133–41
Cardenal F, Lopez Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17: 12–8
Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623–31
Kurihara M, Shimizu H, Tsuboi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemo- therapy. Psychooncology 1999; 8: 355–63
Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere lung cancer study group. J Clin Oncol 2004; 22: 254–61
Moinpour CM, Lyons B, Grevstad PK, et al. Quality of life in advanced non-small cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res 2002; 11: 115–26
Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539–49
Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285–91
Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016–24
Danson S, Middleton MR, O’Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 2003; 98: 542–53
Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group — EORTC 08975. J Clin Oncol 2003; 21: 3909–17
Wachters FM, Van Putten JW, Kramer H, et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer: a phase III trial. Br J Cancer 2003; 89: 1192–9
Burns HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–13
Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical benefit response in advanced non-small cell lung cancer: a multicenter prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001; 12: 1221–30
Jett JR, Su JQ, Krook JE, et al. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol 1994; 12: 2677–81
De Wys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491–7
Acknowledgments
Johan F. Vansteenkiste is the holder of the Eli-Lilly L. Hertel Chair in Respiratory Oncology and the Amgen Fund in Supportive Care at the Catholic University Leuven, Belgium. There are no other sources of funding directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dooms, C.A., Vansteenkiste, J.F. Treatment of patients with advanced non-small cell lung cancer. Am J Cancer 3, 281–290 (2004). https://doi.org/10.2165/00024669-200403050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024669-200403050-00002